Strategy for depleting immune cells implicated in asthma-associated inflammation – Science Daily

Strategy for depleting immune cells implicated in asthma-associated inflammation
Science Daily
Patients with asthma have chronic lung inflammation that results in sporadic narrowing of the airways and difficulty breathing. Symptoms and severity are variable among individuals; however, the cells and inflammatory factors that trigger asthmatic

and more »

View full post on asthma – Google News

Dennis M. Flannelly Joins Phadia as Head of U.S. Marketing and Strategy

Dennis M. Flannelly Joins Phadia as Head of U.S. Marketing and Strategy Says Presss Reports

Today Phadia, the global leader of in vitro diagnostics for allergy, asthma, and autoimmune related diseases, announced that Dennis M. Flannelly has joined the company as Head of U.S. Marketing and Strategy.

Prior to joining Phadia, Mr. Flannelly spent his career at Merck where he held a number of progressively-responsible positions, rising from field sales to lead U.S. and international product launch planning and operational readiness for several targeted $1 billion compounds, including the migraine and insomnia franchises.

He also has extensive experience in respiratory care, having served as Marketing Manager for Merck’s Respiratory Business. In this capacity he defined the strategy and tactical execution for spring allergy campaigns, developed training plans for more than 1,800 sales representatives, and designed a multi-channel marketing program for back-to-school allergy and asthma season.

As Head of Marking and Strategy for Phadia, Mr. Flannelly will oversee all marketing efforts for ImmunoCAP®, the market leader for in vitro allergy testing; develop and execute a broad, multi-channel launch plan for ImmunoCAP Allergen Components, a next-generation allergy test that was cleared by the FDA in June 2011; and develop in-depth marketing efforts to drive accelerated growth for EliA®, the emerging leader and future gold standard for autoimmune testing. This will include expansion of Phadia’s extensive physician and consumer education efforts and healthcare reform initiatives.

David Esposito, President and General Manager of Phadia U.S., said, “Phadia has substantial growth plans in the U.S. to continue our trajectory for ImmunoCAP and seize upon our recent FDA approval for ImmunoCAP Allergen Components, which is the first allergy test to provide visibility into the specific molecules of the allergen that is driving the allergic reaction. In addition, we have just begun our efforts to drive significant growth in the autoimmune market, third largest disease category in the U.S., with our EliA® test offerings. As we continue to build our team, Dennis Flannelly brings a depth of experience from his years at Merck that will serve us well. He has consistently demonstrated the kind of leadership, business acumen, and strategic marketing insight that we need at this time to execute our growth plans.”

Dennis Flannelly added, “I have long admired Phadia and I have seen firsthand the benefits of ImmunoCAP testing from my days leading several initiatives with Merck’s marketing efforts for Singulair®. With Phadia’s recent FDA clearances for next-generation allergy tests, I believe there is a significant opportunity to not only grow the business domestically, but to improve patient care, reduce healthcare costs, and enhance quality of life for people who have allergies or asthma. I’m looking forward to working with David Esposito and his team during this exciting time in Phadia’s history.”

Mr. Flannelly holds a bachelor’s degree in marketing from Villanova University and a master’s in marketing from St. Joseph’s University. He is a Six-Sigma Black Belt and has won several awards for his innovative marketing programs from Merck.

About Phadia

Phadia AB is a global leader in allergy, asthma and autoimmunity diagnostics. Phadia develops, manufactures and markets complete blood test systems to manage and support clinical diagnosis. Phadia has marketing companies in more than 20 countries and distributors in more than 60 countries. For more information please visit

Photos/Multimedia Gallery Available:


Media Contacts:
Michelle Larkin, 610-228-2117
Katie Nicolai, 610-228-2128

Desensitization is new allergy strategy – The Wenatchee World Online

Charlotte Observer

Desensitization is new allergy strategy
The Wenatchee World Online
But new tactics are emerging to help children become desensitized to milk, including one reported last month at the annual meeting of the American Academy of Allergy, Asthma and Immunology in San Francisco. Desensitization involves giving someone tiny
Some Cities Are Worse For AllergiesKCRA Sacramento
Why do more of us have allergies, asthma?Chicago Tribune
Study ranks worst US cities for allergy
NBC Washington –WCVB-TV –WLBZ-TV
all 62 news articles »

View full post on asthma – Google News